The Alpha-9 approach
Alpha-9 has deep expertise in the optimization of peptides, peptidomimetics, and small molecules for radiotherapeutic development. Our systemic approach is fueled by a rich toolkit that includes proprietary fluorine-labeling technology, novel chelators, and various binder and linker modifications (e.g., unnatural amino acids, structural modifications, and novel geometries).
For each target we develop molecules optimized for imaging, dosimetry and therapy. Imaging and dosimetry studies – cost effective, first-in-human studies with the target patient population – demonstrate proof-of-concept for the target while also providing valuable feedback on molecule design.